Skip to content

Next Phase Newsletter

Life Science Nation Next Phase Newsletter

Home
Hot Mandates
Previous Issues
Podcast
Subscribe

t1

December 10, 2012 ~ Next Phase Admin

Published by Next Phase Admin

View all posts by Next Phase Admin

Post navigation

‹ PreviousComparison of early stage funding in the US and EU – who gets more money?

Leave a comment Cancel reply

Δ

Search

Popular Topics

Artificial Intelligence (AI)
Fundraising
Haystack Corner
Hot Mandates
Innovator's Pitch Challenge
Interviews
Longevity & Age-Tech
Partnering
Podcast
Redefining Every Stage Investments (RESI)

Listen to the Podcast

Life Science Nation · Recent Episodes

Top Posts

Life Science Nation (LSN) Launches RESI Asia Japan
Save the Date - Global Family Office BioForum at RESI Boston – Where Active Investors Connect, Collaborate, and Co-Invest
Cross-Border Investor Luncheon at RESI Boston 2026
Drug Development: What Does It Cost, and Who Has The Capital?
Introducing Investor Reverse Pitch at RESI Boston 2026 - Hear directly from the investors shaping the life science and healthcare startup ecosystem
Get Ready for Successful Partnering Meetings
Building the Innovation Bridge Between Japan and the World
The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability
Hot AI Mandate: Early-stage VC Focuses on AI & Data Related Technologies
Hot Investor Mandate: USA Family Office Invests in Global Therapeutics, Devices, and Diagnostics, with Strong Interest in Discovery to Pre-Clinical Technologies

Recent Posts

Hot Investor Mandate: US-Based VC Fund Supports Life Science and Healthcare Companies With Seed Capital, With Strong Interests in AI-Enabled Technologies
Hot Investor Mandate: CVC Arm of Global Pharma Makes Pre-Seed and Seed Investments in Therapeutics and Enabling Technologies, Focusing on US-Based Opportunities
Hot Investor Mandate: International Pharma Company Partners With Early Therapeutic Assets in Oncology and CNS, Seeking Partners Across the Globe
Hot Investor Mandate: Investment Arm of Global Corporation Invests in Therapeutics and Drug Discovery Technologies Targeting Longevity and Age-Related Diseases
Life Science Nation (LSN) Launches RESI Asia Japan

LSN Twitter

Tweets by LSciNation

Follow Next Phase Newsletter on WordPress.com

Contact us

+1 (617) 600-0668

Info@lifesciencenation.com

Archives

Archives

Subscribe

Life Science Nation

RESI Conference Series

Investor Platform Demo

Company Platform Demo

Follow Us

X
LinkedIn

Website Powered by WordPress.com.

Comment
Subscribe Subscribed
- Next Phase Newsletter
- Already have a WordPress.com account? Log in now.

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy